Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

Clin Transpl. 2009:425-9.

Authors

Iris Lee¹, Serban Constantinescu, Avrum Gillespie, Abhishek Swami, Mark Birkenbach, Stephen Leech, Patricio Silva, Andreas Karachristos, John A Daller, Nicole M Sifontis

Affiliation

¹ Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.

PMID: 20524309

No abstract available

Publication types

Case Reports

MeSH terms

B-Lymphocytes / immunology
Boronic Acids / therapeutic use*
Bortezomib
Creatinine / blood
Follow-Up Studies
Graft Rejection / immunology
Graft Rejection / prevention & control*
Hepatitis C / complications
Humans
Immunity, Cellular
Immunity, Humoral
Immunoglobulins, Intravenous / therapeutic use
Kidney Failure, Chronic / complications
Kidney Failure, Chronic / surgery*
Kidney Transplantation / immunology*
Male
Middle Aged
Protease Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
T-Lymphocytes / immunology

Substances

Boronic Acids
Immunoglobulins, Intravenous
Protease Inhibitors
Pyrazines
Bortezomib
Creatinine